A Study of the Quality of Life and Treatment Response to Once Weekly Epoetin Beta (Recormon) Treatment in Anemic Participants With Solid and Lymphoid Malignancies

Quality of Life Related Response to Treatment in Anemic Cancer Patients Receiving Recormon and Efficacy of the Drug Dosage 30,000 IU Once Weekly in Patients With Lymphoproliferative Disorders

This 2 arm study will investigate Quality of Life response in anemic participants with solid and lymphoid malignancies, who are receiving concomitant chemotherapy. Participants with solid and lymphoid malignancies will receive epoetin beta at a dose of 150 international units per kilogram (IU/kg) three times weekly. Participants with lymphoid malignancies will receive epoetin beta 30000 IU once weekly.

Inclusion Criteria:

• Anemia and prescribed treatment with epoetin beta
• Confirmed diagnosis of a solid or lymphoid hematologic malignancy
• Receiving or scheduled to receive chemotherapy
• Life expectancy of greater than or equal to (>=6) months

Exclusion Criteria:

• Anemia after bleeding, hemolytic anemia, megaloblastic anemia, anemia in chronic kidney failure, lever and endocrinology diseases
• Contraindications to epoetin beta
• Administration of epoetin beta during chemotherapy (e.g., on the third day after chemotherapy cycle start)
• Bleeding within one month before and/or during study
• Severe infection within one month before and/or during study
• Inability of participant to fill the questionnaires